Sihs Srl on Muck Rack

Sihs Srl

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sihs

Contact Sihs, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia

|
By Carsten Hirt, Sergio Iannazzo, Sihs Srl, Silvia Chiroli
| link.springer.com
Authors Authors and affiliations Carsten Hirt Sergio Iannazzo Silvia Chiroli Lisa J. McGarry Philipp le Coutre Leif Stenke Torsten Dahlén Jeffrey H. Lipton Original Research Article First Online: 06 June 2019 Abstract Background and Objectives Third-line treatment options for patients with chronic-phase chronic myeloid leukemia include tyrosine kinase inhibitors and allogeneic hematopoietic stem cell transplantation (alloHSCT).
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified